Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Vence

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The Journal of Clinical Investigation|December 3, 2013
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patientsGeok Choo Sim, Natalia Martin-Orozco, Lei Jin, et al.
Psychosomatic Medicine|January 25, 2011
Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomyLorenzo Cohen, Patricia A Parker, Luis Vence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2012
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competencyDavid S Hong, Luis Vence, Gerald Falchook, et al.
Cancer Immunology Research|August 31, 2019
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated MannerLewis Zhichang Shi, Sangeeta Goswami, Tihui Fu, et al.
Plos One|August 8, 2012
Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signalingLorenzo Cohen, Steven W Cole, Anil K Sood, et al.
Nature Communications|March 12, 2015
Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasisRoberto Lande, Elisabetta Botti, Camilla Jandus, et al.
Nature Communications|December 4, 2014
The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasisRoberto Lande, Elisabetta Botti, Camilla Jandus, et al.
Journal for Immunotherapy of Cancer|April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMatthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
Cancer Immunology Research|May 6, 2017
4-1BB-Enhanced Expansion of CD8<sup>+</sup> TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8<sup>+</sup> T CellsMichiko Harao, Marie-Andrée Forget, Jason Roszik, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicitiesSumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The Journal of Clinical Investigation|December 3, 2013
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patientsGeok Choo Sim, Natalia Martin-Orozco, Lei Jin, et al.
Psychosomatic Medicine|January 25, 2011
Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomyLorenzo Cohen, Patricia A Parker, Luis Vence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2012
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competencyDavid S Hong, Luis Vence, Gerald Falchook, et al.
Cancer Immunology Research|August 31, 2019
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated MannerLewis Zhichang Shi, Sangeeta Goswami, Tihui Fu, et al.
Plos One|August 8, 2012
Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signalingLorenzo Cohen, Steven W Cole, Anil K Sood, et al.
Nature Communications|March 12, 2015
Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasisRoberto Lande, Elisabetta Botti, Camilla Jandus, et al.
Nature Communications|December 4, 2014
The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasisRoberto Lande, Elisabetta Botti, Camilla Jandus, et al.
Journal for Immunotherapy of Cancer|April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesMatthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
Cancer Immunology Research|May 6, 2017
4-1BB-Enhanced Expansion of CD8<sup>+</sup> TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8<sup>+</sup> T CellsMichiko Harao, Marie-Andrée Forget, Jason Roszik, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicitiesSumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.
Pageof 3